NFC
TXG icon

Northeast Financial Consultants’s 10x Genomics TXG Stock Holding History

Northeast Financial Consultants’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,691
Closed -$205K – 385
2022
Q1 		$205K Buy
2,691
+853
+46% +$74.6K 0.01% 368
2021
Q4 		$274K Buy
+1,838
New +$282K 0.02% 296

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Northeast Financial Consultants's TXG Position: Q2 2022 in Review

Northeast Financial Consultants sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 2,691 shares — an estimated $205K sold.

Northeast Financial Consultants first reported a position in TXG in Q4 2021 and held it in 2 quarters. The position peaked at $274K in Q4 2021. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.

  • Northeast Financial Consultants reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
  • Northeast Financial Consultants sold 2,691 10x Genomics shares in Q2 2022, an estimated $205K.
  • Northeast Financial Consultants first reported a position in 10x Genomics in Q4 2021 and held it in 2 quarters.
  • Northeast Financial Consultants's 10x Genomics position peaked at $274K in Q4 2021.
  • 254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.

Based on Northeast Financial Consultants's 13F filing for Q2 2022, filed 12 Aug 2022.